RedHill Biopharma Ltd.
RDHL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001553846
In the last 90 days, RedHill Biopharma Ltd. insiders filed 0 open-market purchases and 1 sale; 14 institutions reported holding it in 13F filings for Q2 2026, worth $270.0K in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in RedHill Biopharma Ltd. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −7 vs. Q2 2024
- Shares held
- 5.59K
- −1.94M (−99.7%) vs. Q2 2024
- Total value
- $48.8K
- −$671.0K (−93.2%) vs. Q2 2024
- New holders
- 3
- 0 more added
- Sold out
- 10
- 7 more reduced
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RDHL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $270.0K |
| Q1 2026 | 16 | $386.5K |
| Q4 2025 | 17 | $514.5K |
| Q3 2025 | 14 | $51.2K |
| Q2 2025 | 12 | $37.9K |
| Q1 2025 | 12 | $80.5K |
| Q4 2024 | 11 | $103.5K |
| Q3 2024 | 11 | $48.8K |
| Q2 2024 | 18 | $719.7K |
| Q1 2024 | 17 | $1.40M |
| Q4 2023 | 19 | $449.2K |
| Q3 2023 | 19 | $781.9K |
| Q2 2023 | 21 | $419.2K |
| Q1 2023 | 20 | $1.20M |
| Q4 2022 | 41 | $1.51M |
| Q3 2022 | 43 | $1.46M |
| Q2 2022 | 48 | $3.89M |
| Q1 2022 | 49 | $11.9M |
| Q4 2021 | 57 | $12.5M |
| Q3 2021 | 61 | $24.5M |
| Q2 2021 | 55 | $49.1M |
| Q1 2021 | 64 | $77.4M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding RedHill Biopharma Ltd.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federation des caisses Desjardins du Quebec | 3,992 | $34.9K | 0.00% | −95,885−96.0% | Reduced |
| Rhumbline Advisers | 979 | $8.54K | 0.00% | −17,948−94.8% | Reduced |
| Advisor Group Holdings, Inc. | 396 | $3.46K | 0.00% | +396 | New |
| Morgan Stanley | 180 | $1.57K | 0.00% | −180−50.0% | Reduced |
| Group One Trading, L.P. | 22 | $192 | 0.00% | −593−96.4% | Reduced |
| Capital Performance Advisors LLP | 5 | $44 | 0.00% | +5 | New |
| UBS Group AG | 3 | $26 | 0.00% | −142,382−100.0% | Reduced |
| Bank of America Corp | 2 | $17 | 0.00% | −130−98.5% | Reduced |
| Danske Bank A/S | 2 | $17 | 0.00% | +2 | New |
| IFP Advisors, Inc | 7 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 3 | $0 | 0.00% | −421−99.3% | Reduced |
| Sabby Management, LLC | 0 | $0 | 0.00% | −1,341,189−100.0% | Sold out |
| Gagnon Securities LLC | 0 | $0 | 0.00% | −116,020−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −108,570−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −47,141−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −37,114−100.0% | Sold out |
| We Are One Seven, LLC | 0 | $0 | 0.00% | −15,750−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −13,028−100.0% | Sold out |
| Flputnam Investment Management Co | 0 | $0 | 0.00% | −93−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −11−100.0% | Sold out |